The hypoxia-inducible factor and tumor progression along the angiogenic pathway

International Review of Cytology

Volumn 242, Issue , 2004, Pages 157-213

  Brahimi Horn, M Christiane ^a   Pouysségur, Jacques ^a  

^a CENTRE DE BIOCHIMIE   (France)

Author keywords

Angiogenesis; bHLH PAS protein; Cancer; Hypoxia; Hypoxia inducible factor; Posttranslational modification; prolyl 4 hydroxylase

Indexed keywords

CYTOKINE; ENZYME INHIBITOR; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME; UBIQUITIN;

ACETYLATION; AMINO ACID SEQUENCE; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; DNA BINDING; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HYDROXYLATION; HYPOXIA; ISCHEMIA; METABOLISM; NEOPLASM; NONHUMAN; ONCOGENE; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; TUMOR GROWTH;

EID: 10444223878     PISSN: 00747696     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7696(04)42004-X     Document Type: Article

References (290)

1. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., Semenza G.L. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2001;2911-2916
2. Aguilar R.C., Wendland B. Ubiquitin: Not just for proteasomes anymore. Curr. Opin. Cell Biol. 15:2003;184-190
3. Alam N.A., Rowan A.J., Wortham N.C., Pollard P.J., Mitchell M., Tyrer J.P., Barclay E., Calonje E., Manek S., Adams S.J., Bowers P.W., Burrows N.P., Charles-Holmes R., Cook L.J., Daly B.M., Ford G.P., Fuller L.C., Hadfield-Jones S.E., Hardwick N., Highet A.S., Keefe M., MacDonald-Hull S.P., Potts E.D., Crone M., Wilkinson S., Camacho-Martinez F., Jablonska S., Ratnavel R., MacDonald A., Mann R.J., Grice K., Guillet G., Lewis-Jones M.S., McGrath H., Seukeran D.C., Morrison P.J., Fleming S., Rahman S., Kelsell D., Leigh I., Olpin S., Tomlinson I.P. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 12:2003;1241-1252
4. Arsham A.M., Plas D.R., Thompson C.B., Simon M.C. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 64:2004;3500-3507
5. Bae M.K., Ahn M.Y., Jeong J.W., Bae M.H., Lee Y.M., Bae S.K., Park J.W., Kim K.R., Kim K.W. Jab1 interacts directly with HIF-1 alpha and regulates its stability. J. Biol. Chem. 277:2002;9-12
6. Bangoura G., Yang L.Y., Huang G.W., Wang W. Expression of HIF-2alphaEPAS1 in hepatocellular carcinoma. World J. Gastroenterol. 10:2004;525-530
7. Bannister A.J., Miska E.A. Regulation of gene expression by transcription factor acetylation. Cell. Mol. Life Sci. 57:2000;1184-1192
8. Baysal B.E., Willett-Brozick J.E., Lawrence E.C., Drovdlic C.M., Savul S.A., McLeod D.R., Yee H.A., Brackmann D.E., Slattery W.H. 3rd, Myers E.N., Ferrell R.E., Rubinstein W.S. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med. Genet. 39:2002;178-183
9. Beasley N.J., Wykoff C.C., Watson P.H., Leek R., Turley H., Gatter K., Pastorek J., Cox G.J., Ratcliffe P., Harris A.L. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 61:2001;5262-5267
10. 2-driven proteasomal degradation irrespective of its subcellular localization: Nucleus or cytoplasm. EMBO Rep. 7:2001;615-620
11. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22:2003;4082-4090
12. Berta M., Mazure N., Hattab M., Pouysségur J., Brahimi-Horn M.C. Hypoxia-inducible factor-1a is modified by covalent attachment to SUMO. Keystone Symposia Conference. Biology of Hypoxia: The role of oxygen sensing in development, normal function and disease. 2004;. Silverthorne, CO
13. Bhattacharya S., Ratcliffe P.J. ExCITED about HIF. Nat. Struct. Biol. 10:2003;501-503
14. Bhattacharya S., Michels C.L., Leung M.K., Arany Z.P., Kung A.L., Livingston D.M. Functional role of p35srj, a novel p300CBP binding protein, during transactivation by HIF-1. Genes Dev. 13:1999;64-75
15. Bilton R.L., Booker G.W. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur. J. Biochem. 270:2003;791-798
16. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:2000;4693-4696
17. Birner P., Gatterbauer B., Oberhuber G., Schindl M., Rossler K., Prodinger A., Budka H., Hainfellner J.A. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer. 92:2001a;165-171
18. Birner P., Schindl M., Obermair A., Breitenecker G., Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7:2001b;1661-1668
19. Blankenship C., Naglich J.G., Whaley J.M., Seizinger B., Kley N. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene. 18:1999;1529-1535
20. Blouin C.C., Page E.L., Soucy G.M., Richard D.E. Hypoxic gene activation by lipopolysaccharide in macrophages: Implication of hypoxia-inducible factor 1alpha. Blood. 103:2004;1124-1130
21. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 4:2003;133-146
22. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., Abeloff M.D., Simons J.W., van Diest P.J., van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93:2001;309-314
23. Bos R., van der Groep P., Greijer A.E., Shvarts A., Meijer S., Pinedo H.M., Semenza G.L., van Diest P.J., van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 97:2003;1573-1581
24. Brahimi-Horn M.C., Pouysségur J. Ubiquitin: Signal and proteasome inhibition. Crit. Rev. Oncol.Hepatol. 2004;. (in press)
25. Brahimi-Horn, M.C., and Pouysségur, J. (2005) Signalling via the hypoxia-inducible factor-1alpha (HIF-1a) requires multiple post-translational modifications. Cell. Signal. 7 1-9.
26. Brivanlou A.H., Darnell J.E. Jr. Signal transduction and the control of gene expression. Science. 295:2002;813-818
27. Brizel D.M., Schroeder T., Scher R.L., Walenta S., Clough R.W., Dewhirst M.W., Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51:2001;349-353
28. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer. 4:2004;437-447
29. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA. 97:2000;9082-9087
30. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:2001;1337-1340
31. Burri P., Djonov V., Aebersold D.M., Lindel K., Studer U., Altermatt H.J., Mazzucchelli L., Greiner R.H., Gruber G. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56:2003;494-501
32. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9:2003;653-660
33. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439
34. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E., Keshet E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490
35. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 20:2000;402-415
36. Carrozza M.J., Utley R.T., Workman J.L., Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet. 19:2003;321-329
37. Chan W.K., Yao G., Gu Y.Z., Bradfield C.A. Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation. J. Biol. Chem. 274:1999;12115-12123
38. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276:2001;9519-9525
39. Chen D., Li M., Luo J., Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J. Biol. Chem. 278:2003;13595-13598
40. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:2000;25733-25741
41. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., Nemery B., Dewerchin M., Van Veldhoven P., Plate K., Moons L., Collen D., Carmeliet P. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8:2002;702-710
42. Compernolle V., Brusselmans K., Franco D., Moorman A., Dewerchin M., Collen D., Carmeliet P. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha. Cardiovasc. Res. 60:2003;569-579
43. Coumailleau P., Poellinger L., Gustafsson J.A., Whitelaw M.L. Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity. J. Biol. Chem. 270:1995;25291-25300
44. Cowden K.D., Simon M.C. The bHLHPAS factor MOP3 does not participate in hypoxia responses. Biochem. Biophys. Res. Commun. 290:2002;1228-1236
45. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., Firestein G.S., Gerber H.P., Ferrara N., Johnson R.S. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 112:2003;645-657
46. Crews S.T. Control of cell lineage-specific development and transcription by bHLH-PAS proteins. Genes Dev. 12:1998;607-620
47. Crews S.T., Fan C.M. Remembrance of things PAS: Regulation of development by bHLH-PAS proteins. Curr. Opin. Genet. Dev. 9:1999;580-587
48. Crews S.T., Thomas J.B., Goodman C.S. The Drosophila single-minded gene encodes a nuclear protein with sequence similarity to the per gene product. Cell. 52:1988;143-151
49. Dalgard C.L., Lu H., Mohyeldin A., Verma A. Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. Biochem. J. 380:2004;419-424
50. Dames S.A., Martinez-Yamout M., De Guzman R.N., Dyson H.J., Wright P.E. Structural basis for Hif-1 alphaCBP recognition in the cellular hypoxic response. Proc. Natl. Acad. Sci. USA. 99:2002;5271-5276
51. Dann C.E. 3rd, Bruick R.K., Deisenhofer J. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc. Natl. Acad. Sci. USA. 99:2002;15351-15356
52. Denison M.S., Fisher J.M., Whitlock J.P. Jr. Protein-DNA interactions at recognition sites for the dioxin-Ah receptor complex. J. Biol. Chem. 264:1989;16478-16482
53. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J.M., Nusgens B.V., Castronovo V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 21:2002;427-436
54. Dial R., Sun Z.Y., Freedman S.J. Three conformational states of the p300 CH1 domain define its functional properties. Biochemistry. 42:2003;9937-9945
55. Drutel G., Kathmann M., Heron A., Schwartz J.C., Arrang J.M. Cloning and selective expression in brain and kidney of ARNT2 homologous to the Ah receptor nuclear translocator (ARNT). Biochem. Biophys. Res. Commun. 225:1996;333-339
56. Drutel G., Kathmann M., Heron A., Gros C., Mace S., Schwartz J.C., Arrang J.M. Two splice variants of the hypoxia-inducible factor HIF-1alpha as potential dimerization partners of ARNT2 in neurons. Eur. J. Neurosci. 12:2000;3701-3708
57. Duan D.R., Pause A., Burgess W.H., Aso T., Chen D.Y., Garrett K.P., Conaway R.C., Conaway J.W., Linehan W.M., Klausner R.D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 269:1995;1402-1406
58. Elkins J.M., Hewitson K.S., McNeill L.A., Seibel J.F., Schlemminger I., Pugh C.W., Ratcliffe P.J., Schofield C.J. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. J. Biol. Chem. 278:2003;1802-1806
59. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA. 94:1997;4273-4278
60. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., Poellinger L., Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: Their stabilization and redox signal-induced interaction with CBPp300. EMBO J. 18:1999;1905-1914
61. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., Ratcliffe P.J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54
62. Erez N., Milyavsky M., Goldfinger N., Peles E., Gudkov A.V., Rotter V. Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene. 21:2002;6713-6721
63. Erez N., Milyavsky M., Eilam R., Shats I., Goldfinger N., Rotter V. Expression of prolyl-hydroxylase-1 (PHD1EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res. 63:2003;8777-8783
64. Erez N., Stambolsky P., Shats I., Milyavsky M., Kachko T., Rotter V. Hypoxia-dependent regulation of PHD1: Cloning and characterization of the human PHD1EGLN2 gene promoter. FEBS Lett. 567:2004;311-315
65. Favreau L.V., Pickett C.B. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. J. Biol. Chem. 266:1991;4556-4561
66. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 59:1999;3915-3918
67. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442
68. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:2004;391-400
69. Fisher J.M., Wu L., Denison M.S., Whitlock J.P. Jr. Organization and function of a dioxin-responsive enhancer. J. Biol. Chem. 265:1990;9676-9681
70. Flamme I., Frohlich T., von Reutern M., Kappel A., Damert A., Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech. Dev. 63:1997;51-60
71. Fluge O., Bruland O., Akslen L.A., Varhaug J.E., Lillehaug J.R. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene. 21:2002;5056-5068
72. Folkman J., Hahnfeldt P., Hlatky L. Cancer: Looking outside the genome. Nat. Rev. Mol. Cell. Biol. 1:2000;76-79
73. Freedman S.J., Sun Z.Y., Poy F., Kung A.L., Livingston D.M., Wagner G., Eck M.J. Structural basis for recruitment of CBPp300 by hypoxia-inducible factor-1 alpha. Proc. Natl. Acad. Sci. USA. 99:2002;5367-5372
74. Freedman S.J., Sun Z.Y., Kung A.L., France D.S., Wagner G., Eck M.J. Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat. Struct. Biol. 10:2003;504-512
75. Frei C., Edgar B.A. Drosophila cyclin DCdk4 requires Hif-1 prolyl hydroxylase to drive cell growth. Dev. Cell. 6:2004;241-251
76. Freiman R.N., Tjian R. Regulating the regulators: Lysine modifications make their mark. Cell. 112:2003;11-17
77. Fujisawa-Sehara A., Sogawa K., Yamane M., Fujii-Kuriyama Y. Characterization of xenobiotic responsive elements upstream from the drug-metabolizing cytochrome P-450c gene: A similarity to glucocorticoid regulatory elements. Nucleic Acids Res. 15:1987;4179-4191
78. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277:2002;38205-38211
79. Fukunaga B.N., Probst M.R., Reisz-Porszasz S., Hankinson O. Identification of functional domains of the aryl hydrocarbon receptor. J. Biol. Chem. 270:1995;29270-29278
80. Gardner L.B., Li Q., Park M.S., Flanagan W.M., Semenza G.L., Dang C.V. Hypoxia inhibits G1S transition through regulation of p27 expression. J. Biol. Chem. 276:2001;7919-7926
81. Gendron R.L., Adams L.C., Paradis H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. Dev. Dyn. 218:2000;300-315
82. Gendron R.L., Good W.V., Adams L.C., Paradis H. Suppressed expression of tubedown-1 in retinal neovascularization of proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 42:2001;3000-3007
83. Giatromanolaki A., Sivridis E., Kouskoukis C., Gatter K.C., Harris A.L., Koukourakis M.I. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 13:2003;493-501
84. Gnarra J.R., Ward J.M., Porter F.D., Wagner J.R., Devor D.E., Grinberg A., Emmert-Buck M.R., Westphal H., Klausner R.D., Linehan W.M. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA. 94:1997;9102-9107
85. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., Johnson R.S. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23:2003;359-369
86. Gothié E., Richard D.E., Berra E., Pages G., Pouysségur J. Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J. Biol. Chem. 275:2000;6922-6927
87. Gradin K., McGuire J., Wenger R.H., Kvietikova I., fhitelaw M.L., Toftgard R., Tora L., Gassmann M., Poellinger L. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor. Mol. Cell. Biol. 16:1996;5221-5231
88. Gradin K., Takasaki C., Fujii-Kuriyama Y., Sogawa K. The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine. J. Biol. Chem. 277:2002;23508-23514
89. Green S.L., Freiberg R.A., Giaccia A.J. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol. Cell. Biol. 21:2001;1196-1206
90. Grossman S.R., Deato M.E., Brignone C., Chan H.M., Kung A.L., Tagami H., Nakatani Y., Livingston D.M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 300:2003;342-344
91. Groulx I., Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22:2002;5319-5336
92. Gruber G., Greiner R.H., Hlushchuk R., Aebersold D.M., Altermatt H.J., Berclaz G., Djonov V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: An independent prognostic parameter? Breast Cancer Res. 6:2004;R191-R198
93. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer. 4:2004;361-370
94. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 7:1998;205-213
95. Gu Y.Z., Hogenesch J.B., Bradfield C.A. The PAS superfamily: Sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol. 40:2000;519-561
96. Haase V.H., Glickman J.N., Socolovsky M., Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA. 98:2001;1583-1588
97. Haddad J.J. Oxygen sensing and oxidantredox-related pathways. Biochem. Biophys. Res. Commun. 316:2004;969-977
98. Haddad J.J., Land S.C. A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS Lett. 505:2001;269-274
99. Hagen T., Taylor C.T., Lam F., Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: Effect on HIF 1alpha. Science. 302:2003;1975-1978
100. Halterman M.W., Miller C.C., Federoff H.J. Hypoxia-inducible factor-1alpha mediates hypoxia-induced delayed neuronal death that involves p53. J. Neurosci. 19:1999;6818-6824
101. Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 35:1995;307-340
102. Hara S., Hamada J., Kobayashi C., Kondo Y., Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: Suppression of HIF-mediated gene expression by HIF-3alpha. Biochem. Biophys. Res. Commun. 287:2001;808-813
103. Hedley D., Pintilie M., Woo J., Morrison A., Birle D., Fyles A., Milosevic M., Hill R. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res. 9:2003;5666-5674
104. Hefti M.H., Francoijs K.J., de Vries S.C., Dixon R., Vervoort J. The PAS fold: A redefination of the PAS domain based upon structural prediction. Eur. J. Biochem. 271:2004;1198-1208
105. Hemberger M., Himmelbauer H., Neumann H.P., Plate K.H., Schwarzkopf G., Fundele R. Expression of the von Hippel-Lindau-binding protein-1 (Vbp1) in fetal and adult mouse tissues. Hum. Mol. Genet. 8:1999;229-236
106. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W., Elkins J.M., Oldham N.J., Bhattacharya S., Gleadle J.M., Ratcliffe P.J., Pugh C.W., Schofield C.J. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277:2002;26351-26355
107. Hirose K., Morita M., Ema M., Mimura J., Hamada H., Fujii H., Saijo Y., Gotoh O., Sogawa K., Fujii-Kuriyama Y. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helixPAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol. Cell. Biol. 16:1996;1706-1713
108. Hockel M., Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93:2001;266-276
109. Hoffman E.C., Reyes H., Chu F.F., Sander F., Conley L.H., Brooks B.A., Hankinson O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science. 252:1991;954-958
110. Hogenesch J.B., Chan W.K., Jackiw V.H., Brown R.C., Gu Y.Z., Pray-Grant M., Perdew G.H., Bradfield C.A. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J. Biol. Chem. 272:1997;8581-8593
111. Hogenesch J.B., Gu Y.Z., Jain S., Bradfield C.A. The basic-helix-loop- helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc. Natl. Acad. Sci. USA. 95:1998;5474-5479
112. Hon W.C., Wilson M.I., Harlos K., Claridge T.D., Schofield C.J., Pugh C.W., Maxwell P.H., Ratcliffe P.J., Stuart D.I., Jones E.Y. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature. 417:2002;975-978
113. Hopfl G., Wenger R.H., Ziegler U., Stallmach T., Gardelle O., Achermann R., Wergin M., Kaser-Hotz B., Saunders H.M., Williams K.J., Stratford I.J., Gassmann M., Desbaillets I. Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res. 62:2002;2962-2970
114. Huang J., Zhao Q., Mooney S.M., Lee F.S. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J. Biol. Chem. 277:2002;39792-39800
115. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 95:1998;7987-7992
116. Ikuta T., Eguchi H., Tachibana T., Yoneda Y., Kawajiri K. Nuclear localization and export signals of the human aryl hydrocarbon receptor. J. Biol. Chem. 273:1998;2895-2904
117. Iliopoulos O., Kibel A., Gray S., Kaelin W.G. Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:1995;822-826
118. Iliopoulos O., Ohh M., Kaelin W.G. Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. USA. 95:1998;11661-11666
119. Imanishi T., Itoh T., Suzuki Y., O'Donovan C., Fukuchi S., Koyanagi K.O., Barrero R.A., Tamura T., Yamaguchi-Kabata Y., Tanino M., Yura K., Miyazaki S., Ikeo K., Homma K., Kasprzyk A., Nishikawa T., Hirakawa M., Thierry-Mieg J., Thierry-Mieg D., Ashurst J., Jia L., Nakao M., Thomas M.A., Mulder N., Karavidopoulou Y., Jin L., Kim S., Yasuda T., Lenhard B., Eveno E., Yamasaki C., Takeda J.I., Gough C., Hilton P., Fujii Y., Sakai H., Tanaka S., Amid C., Bellgard M., Bonaldo Mde F., Bono H., Bromberg S.K., Brookes A.J., Bruford E., Carninci P., Chelala C., Couillault C., Souza S.J., Debily M.A., Devignes M.D., Dubchak I., Endo T., Estreicher A., Eyras E., Fukami-Kobayashi K., Gopinath G.R., Graudens E., Hahn Y., Han M., Han Z.G., Hanada K., Hanaoka H., Harada E., Hashimoto K., Hinz U., Hirai M., Hishiki T., Hopkinson I., Imbeaud S., Inoko H., Kanapin A., Kaneko Y., Kasukawa T., Kelso J., Kersey P., Kikuno R., Kimura K., Korn B., Kuryshev V., Makalowska I., Makino T., Mano S., Mariage-Samson R., Mashima J., Matsuda H., Mewes H.W., Minoshima S., Nagai K., Nagasaki H., Nagata N., Nigam R., Ogasawara O., Ohara O., Ohtsubo M., Okada N., Okido T., Oota S., Ota M., Ota T., Otsuki T., Piatier-Tonneau D., Poustka A., Ren S.X., Saitou N., Sakai K., Sakamoto S., Sakate R., Schupp I., Servant F., Sherry S., Shiba R., Shimizu N., Shimoyama M., Simpson A.J., Soares B., Steward C., Suwa M., Suzuki M., Takahashi A., Tamiya G., Tanaka H., Taylor T., Terwilliger J.D., Unneberg P., Veeramachaneni V., Watanabe S., Wilming L., Yasuda N., Yoo H.S., Stodolsky M., Makalowski W., Go M., Nakai K., Takagi T., Kanehisa M., Sakaki Y., Quackenbush J., Okazaki Y., Hayashizaki Y., Hide W., Chakraborty R., Nishikawa K., Sugawara H., Tateno Y., Chen Z., Oishi M., Tonellato P., Apweiler R., Okubo K., Wagner L., Wiemann S., Strausberg R.L., Isogai T., Auffray C., Nomura N., Gojobori T., Sugano S. Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol. 2:2004;856-875
120. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1alpha-degradative pathway. J. Biol. Chem. 277:2002;29936-29944
121. Isaacs J.S., Jung Y.J., Neckers L. Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway. J. Biol. Chem. 279:2004;16128-16135
122. Ivan M., Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11:2001;27-34
123. Ivan M., Haberberger T., Gervasi D.C., Michelson K.S., Gunzler V., Kondo K., Yang H., Sorokina I., Conaway R.C., Conaway J.W., Kaelin W.G. Jr. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA. 99:2002;13459-13464
124. Ivanov S., Liao S.Y., Ivanova A., Danilkovitch-Miagkova A., Tarasova N., Weirich G., Merrill M.J., Proescholdt M.A., Oldfield E.H., Lee J., Zavada J., Waheed A., Sly W., Lerman M.I., Stanbridge E.J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158:2001;905-919
125. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y., Semenza G.L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha. Genes Dev. 12:1998;149-162
126. 2-regulated prolyl hydroxylation. Science. 292:2001;468-472
127. Jain S., Maltepe E., Lu M.M., Simon C., Bradfield C.A. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech. Dev. 73:1998;117-123
128. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 111:2002;709-720
129. Jesenberger V., Jentsch S. Deadly encounter: Ubiquitin meets apoptosis. Nat. Rev. Mol. Cell. Biol. 3:2002;112-121
130. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res. 57:1997a;5328-5335
131. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272:1997b;19253-19260
132. Jubb A.M., Pham T.Q., Hanby A.M., Frantz G.D., Peale F.V., Wu T.D., Koeppen H.W., Hillan K.J. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J. Clin. Pathol. 57:2004;504-512
133. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682
134. Kageyama Y., Koshiji M., To K.K., Tian Y.M., Ratcliffe P.J., Huang L.E. Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. FASEB J. 18:2004;1028-1030
135. Kallio P.J., Okamoto K., O'Brien S., Carrero P., Makino Y., Tanaka H., Poellinger L. Signal transduction in hypoxic cells: Inducible nuclear translocation and recruitment of the CBPp300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 17:1998;6573-6586
136. Kamura T., Koepp D.M., Conrad M.N., Skowyra D., Moreland R.J., Iliopoulos O., Lane W.S., Kaelin W.G. Jr., Elledge S.J., Conaway R.C., Harper J.W., Conaway J.W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 284:1999;657-661
137. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739
138. Kewley R.J., Whitelaw M.L., Chapman-Smith A. The mammalian basic helix-loop-helixPAS family of transcriptional regulators. Int. J. Biochem. Cell Biol. 36:2004;189-204
139. Kibel A., Iliopoulos O., DeCaprio J.A., Kaelin W.G. Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science. 269:1995;1444-1446
140. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Chung H.Y., Kim C.W., Kim K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7:2001;437-443
141. Kim W., Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13:2003;55-60
142. Kitada T., Seki S., Sakaguchi H., Sawada T., Hirakawa K., Wakasa K. Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma. Histopathology. 43:2003;550-555
143. Kivirikko K.I., Myllyla R. Posttranslational enzymes in the biosynthesis of collagen: Intracellular enzymes. Methods Enzymol. 82:(Pt. A):1982;245-304
144. Kleymenova E., Everitt J.I., Pluta L., Portis M., Gnarra J.R., Walker C.L. Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Carcinogenesis. 25:2004;309-315
145. Knowles H.J., Raval R.R., Harris A.L., Ratcliffe P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63:2003;1764-1768
146. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279:2004;9899-9904
147. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246
148. Kondo K., Kim W.Y., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1:2003;E83
149. Koshiji M., Kageyama Y., Pete E.A., Horikawa I., Barrett J.C., Huang L.E. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23:2004;1949-1956
150. Kotch L.E., Iyer N.V., Laughner E., Semenza G.L. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev. Biol. 209:1999;254-267
151. Koukourakis M.I., Giatromanolaki A., Sivridis E., Pastorek J., Karapantzos I., Gatter K.C., Harris A.L. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 59:2004;67-71
152. Kouzarides T. Acetylation: A regulatory modification to rival phosphorylation? EMBO J. 19:2000;1176-1179
153. Kozak K.R., Abbott B., Hankinson O. ARNT-deficient mice and placental differentiation. Dev. Biol. 191:1997;297-305
154. Krieg M., Haas R., Brauch H., Acker T., Flamme I., Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 19:2000;5435-5443
155. Kubota M., Sogawa K., Kaizu Y., Sawaya T., Watanabe J., Kawajiri K., Gotoh O., Fujii-Kuriyama Y. Xenobiotic responsive element in the 5′-upstream region of the human P-450c gene. J. Biochem. (Tokyo). 110:1991;232-236
156. Kung A.L., Wang S., Klco J.M., Kaelin W.G., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6:2000;1335-1340
157. Kuznetsova A.V., Meller J., Schnell P.O., Nash J.A., Ignacak M.L., Sanchez Y., Conaway J.W., Conaway R.C., Czyzyk-Krzeska M.F. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc. Natl. Acad. Sci. USA. 100:2003;2706-2711
158. Ladoux A., Frelin C. Cardiac expressions of HIF-1 alpha and HLFEPAS, two basic loop helixPAS domain transcription factors involved in adaptative responses to hypoxic stresses. Biochem. Biophys. Res. Commun. 240:1997;552-556
159. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16:2002;1466-1471
160. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: Novel mechanism for hif-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:2001;3995-4004
161. Lee C., Kim S.J., Jeong D.G., Lee S.M., Ryu S.E. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J. Biol. Chem. 278:2003;7558-7563
162. Lee E., Yim S., Lee S.K., Park H. Two transactivation domains of hypoxia-inducible factor-1alpha regulated by the MEK-1p42p44 MAPK pathway. Mol. Cells. 14:2002;9-15
163. Lee M.J., Kim J.Y., Suk K., Park J.H. Identification of the hypoxia-inducible factor 1 alpha-responsive HGTD-P gene as a mediator in the mitochondrial apoptotic pathway. Mol. Cell. Biol. 24:2004;3918-3927
164. Lewis M.D., Roberts B.J. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein. Oncogene. 22:2003;3992-3997
165. Lewis M.D., Roberts B.J. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. Oncogene. 23:2004;2315-2323
166. Li H., Ko H.P., Whitlock J.P. Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF 1alpha. J. Biol. Chem. 271:1996;21262-21267
167. Li Z., Na X., Wang D., Schoen S.R., Messing E.M., Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 277:2002a;4656-4662
168. Li Z., Wang D., Na X., Schoen S.R., Messing E.M., Wu G. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem. Biophys. Res. Commun. 294:2002b;700-709
169. Li Z., Wang D., Na X., Schoen S.R., Messing E.M., Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J. 22:2003;1857-1867
170. Lieb M.E., Menzies K., Moschella M.C., Ni R., Taubman M.B. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem. Cell Biol. 80:2002;421-426
171. Line A., Stengrevics A., Slucka Z., Li G., Jankevics E., Rees R.C. Serological identification and expression analysis of gastric cancer-associated genes. Br. J. Cancer. 86:2002;1824-1830
172. Linke S., Stojkoski C., Kewley R.J., Booker G.W., Whitelaw M.L., Peet D.J. Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor inhibiting HIF. J. Biol. Chem. 279:2004;14391-14397
173. Lipscomb E.A., Sarmiere P.D., Freeman R.S. SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons. J. Biol. Chem. 276:2001;5085-5092
174. Littlewood T.D., Evan G.I. Transcription factors 2: Helix-loop-helix. Protein Profile. 2:1995;621-702
175. Lu H., Forbes R.A., Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277:2002;23111-23115
176. Mabjeesh N.J., Willard M.T., Frederickson C.E., Zhong H., Simons J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptorphosphatidylinositol 3′-kinaseprotein kinase B in prostate cancer cells. Clin. Cancer Res. 9:2003;2416-2425
177. Mack F.A., Rathmell W.K., Arsham A.M., Gnarra J., Keith B., Simon M.C. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 3:2003;75-88
178. Mahon P.C., Hirota K., Semenza G.L. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15:2001;2675-2686
179. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10:2004;594-601
180. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature. 414:2001;550-554
181. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature. 386:1997;403-407
182. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 1:2002;247-255
183. Marxsen J.H., Stengel P., Doege K., Heikkinen P., Jokilehto T., Wagner T., Jelkmann W., Jaakkola P., Metzen E. Hypoxia-inducible factor-1 promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem. J. 381:(Pt. 3):2004;761-767
184. Masson N., Ratcliffe P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J. Cell Sci. 116:2003;3041-3049
185. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:2001;5197-5206
186. Mateo J., Garcia-Lecea M., Cadenas S., Hernandez C., Moncada S. Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem. J. 376:2003;537-544
187. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA. 94:1997;8104-8109
188. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275
189. Maxwell P.H., Pugh C.W., Ratcliffe P.J. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 11:2001;293-299
190. Maynard M.A., Qi H., Chung J., Lee E.H., Kondo Y., Hara S., Conaway R.C., Conaway J.W., Ohh M. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem. 278:2003;11032-11040
191. Mazure N.M., Chauvet C., Bois-Joyeux B., Bernard M.A., Nacer-Cherif H., Danan J.L. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: Characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res. 62:2002;1158-1165
192. Mazure N.M., Brahimi-Horn M.C., Berta M., Benizri E., Bilton R.L., Dayan F., Ginouves A., Berra E., Pouysségur J. HIF-1: Master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNA. Biochem. Pharmacol. 68:2004;971-980
193. McNeill L.A., Hewitson K.S., Claridge T.D., Seibel J.F., Horsfall L.E., Schofield C.J. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem. J. 367:2002;571-575
194. Mekhail K., Gunaratnam L., Bonicalzi M.E., Lee S. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat. Cell Biol. 6:2004;642-647
195. Menzies K., Liu B., Kim W.J., Moschella M.C., Taubman M.B. Regulation of the SM-20 prolyl hydroxylase gene in smooth muscle cells. Biochem. Biophys. Res. Commun. 317:2004;801-810
196. Metzen E., Berchner-Pfannschmidt U., Stengel P., Marxsen J.H., Stolze I., Klinger M., Huang W.Q., Wotzlaw C., Hellwig-Burgel T., Jelkmann W., Acker H., Fandrey J. Intracellular localisation of human HIF-1 alpha hydroxylases: Implications for oxygen sensing. J. Cell Sci. 116:2003;1319-1326
197. Min J.H., Yang H., Ivan M., Gertler F., Kaelin W.G. Jr., Pavletich N.P. Structure of an HIF-1alpha-p VHL complex: Hydroxyproline recognition in signaling. Science. 296:2002;1886-1889
198. Mullen J.R., Kayne P.S., Moerschell R.P., Tsunasawa S., Gribskov M., Colavito-Shepanski M., Grunstein M., Sherman F., Sternglanz R. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J. 8:1989;2067-2075
199. Muratani M., Tansey W.P. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 4:2003;192-201
200. Murre C., McCaw P.S., Vaessin H., Caudy M., Jan L.Y., Jan Y.N., Cabrera C.V., Buskin J.N., Hauschka S.D., Lassar A.B., et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell. 58:1989;537-544
201. Na X., Duan H.O., Messing E.M., Schoen S.R., Ryan C.K., di Sant'Agnese P.A., Golemis E.A., Wu G. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J. 22:2003;4249-4259
202. Nakayama K., Kanzaki A., Hata K., Katabuchi H., Okamura H., Miyazaki K., Fukumoto M., Takebayashi Y. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett. 176:2002;215-223
203. Niemann S., Muller U., Engelhardt D., Lohse P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC. Hum. Genet. 113:2003;92-94
204. Okuda H., Saitoh K., Hirai S., Iwai K., Takaki Y., Baba M., Minato N., Ohno S., Shuin T. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 276:2001;43611-43617
205. Olive P.L., Aquino-Parsons C., MacPhail S.H., Liao S.Y., Raleigh J.A., Lerman M.I., Stanbridge E.J. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61:2001;8924-8929
206. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Dorpe J.V., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Bosch L.V., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28:2001;131-138
207. O'Rourke J.F., Tian Y.M., Ratcliffe P.J., Pugh C.W. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: Comparison with hypoxia-inducible factor-1alpha. J. Biol. Chem. 274:1999;2060-2071
208. Page E.L., Robitaille G.A., Pouysségur J., Richard D.E. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J. Biol. Chem. 277:2002;48403-48409
209. Paradis H., Liu C.Y., Saika S., Azhar M., Doetschman T., Good W.V., Nayak R., Laver N., Kao C.W., Kao W.W., Gendron R.L. Tubedown-1 in remodeling of the developing vitreal vasculature in vivo and regulation of capillary outgrowth in vitro. Dev. Biol. 249:2002;140-155
210. Park E.C., Szostak J.W. ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity. EMBO J. 11:1992;2087-2093
211. Paul S.A., Simons J.W., Mabjeesh N.J. HIF at the crossroads between ischemia and carcinogenesis. J. Cell. Physiol. 200:2004;20-30
212. Pause A., Lee S., Worrell R.A., Chen D.Y., Burgess W.H., Linehan W.M., Klausner R.D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA. 94:1997;2156-2161
213. Peng J., Zhang L., Drysdale L., Fong G.H. The transcription factor EPAS-1hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc. Natl. Acad. Sci. USA. 97:2000;8386-8391
214. Pickart C.M., Cohen R.E. Proteasomes and their kin: Proteases in the machine age. Nat. Rev. Mol. Cell. Biol. 5:2004;177-187
215. Powell W.H., Hahn M.E. Identification and functional characterization of hypoxia-inducible factor 2alpha from the estuarine teleost, Fundulus heteroclitus: Interaction of HIF-2alpha with two ARNT2 splice variants. J. Exp. Zool. 294:2002;17-29
216. Powis G., Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther. 3:2004;647-654
217. Prives C., Manley J.L. Why is p53 acetylated? Cell. 107:2001;815-818
218. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., Ratcliffe P.J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J. Biol. Chem. 272:1997;11205-11214
219. Qi H., Gervais M.L., Li W., DeCaprio J.A., Challis J.R., Ohh M. Molecular cloning and characterization of the von Hippel-Lindau-like protein. Mol. Cancer Res. 2:2004;43-52
220. Qin C., Wilson C., Blancher C., Taylor M., Safe S., Harris A.L. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis. Clin. Cancer Res. 7:2001;818-823
221. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:2000;34-44
222. Richard D.E., Berra E., Gothie E., Roux D., Pouysségur J. p42p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274:1999;32631-32637
223. Richard D.E., Vouret-Craviari V., Pouysségur J. Angiogenesis and G-protein-coupled receptors: Signals that bridge the gap. Oncogene. 20:2001;1556-1562
224. Ruas J.L., Poellinger L., Pereira T. Functional analysis of hypoxia-inducible factor-1 alpha-mediated transactivation. Identification of amino acid residues critical for transcriptional activation andor interaction with CREB-binding protein. J. Biol. Chem. 277:2002;38723-38730
225. Rushmore T.H., King R.G., Paulson K.E., Pickett C.B. Regulation of glutathione S-transferase Ya subunit gene expression: Identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc. Natl. Acad. Sci. USA. 87:1990;3826-3830
226. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015
227. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015
228. Saatcioglu F., Perry D.J., Pasco D.S., Fagan J.B. Aryl hydrocarbon (Ah) receptor DNA-binding activity. Sequence specificity and Zn2+ requirement. J. Biol. Chem. 265:1990;9251-9258
229. Sang N., Stiehl D.P., Bohensky J., Leshchinsky I., Srinivas V., Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem. 278:2003;14013-14019
230. Schindl M., Schoppmann S.F., Samonigg H., Hausmaninger H., Kwasny W., Gnant M., Jakesz R., Kubista E., Birner P., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8:2002;1831-1837
231. Schoenfeld A., Davidowitz E.J., Burk R.D. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA. 95:1998;8817-8822
232. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell. Biol. 5:2004;343-354
233. Schofield C.J., Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr. Opin. Struct. Biol. 9:1999;722-731
234. Schwickert G., Walenta S., Sundfor K., Rofstad E.K., Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 55:1995;4757-4759
235. Seeler J.S., Dejean A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell. Biol. 4:2003;690-699
236. Semenza G.L. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol. Med. 8:2002;S62-S67
237. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:2003;721-732
238. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12:1992;5447-5454
239. Semenza G.L., Nejfelt M.K., Chi S.M., Antonarakis S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc. Natl. Acad. Sci. USA. 88:1991;5680-5684
240. Shibaji T., Nagao M., Ikeda N., Kanehiro H., Hisanaga M., Ko S., Fukumoto A., Nakajima Y. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 23:2003;4721-4727
241. Shoshani T., Faerman A., Mett I., Zelin E., Tenne T., Gorodin S., Moshel Y., Elbaz S., Budanov A., Chajut A., Kalinski H., Kamer I., Rozen A., Mor O., Keshet E., Leshkowitz D., Einat P., Skaliter R., Feinstein E. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22:2002;2283-2293
242. Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., Gutkind J.S. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 60:2000;4873-4880
243. Sogawa K., Nakano R., Kobayashi A., Kikuchi Y., Ohe N., Matsushita N., Fujii-Kuriyama Y. Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional regulation. Proc. Natl. Acad. Sci. USA. 92:1995;1936-1940
244. Sohda M., Ishikawa H., Masuda N., Kato H., Miyazaki T., Nakajima M., Fukuchi M., Manda R., Fukai Y., Sakurai H., Kuwano H. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int. J. Cancer. 110:2004;838-844
245. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61:2001;6669-6673
246. Sowter H.M., Ferguson M., Pym C., Watson P., Fox S.B., Han C., Harris A.L. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J. Pathol. 201:2003;573-580
247. Stiehl D.P., Jelkmann W., Wenger R.H., Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 512:2002;157-162
248. Sugiura N., Adams S.M., Corriveau R.A. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J. Biol. Chem. 278:2003;40113-40120
249. Sumbayev V.V., Budde A., Zhou J., Brune B. HIF-1 alpha protein as a target for S-nitrosation. FEBS Lett. 535:2003;106-112
250. Suzuki H., Tomida A., Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene. 20:2001;5779-5788
251. Swanson H.I., Chan W.K., Bradfield C.A. DNA binding specificities and pairing rules of the Ah receptor, ARNT, and SIM proteins. J. Biol. Chem. 270:1995;26292-26302
252. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:2000;411-421
253. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19:2000;4298-4309
254. Taylor M.S. Characterization and comparative analysis of the EGLN gene family. Gene. 275:2001;125-132
255. Tian H., McKnight S.L., Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:1997;72-82
256. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12:1998;3320-3324
257. Tojo M., Matsuzaki K., Minami T., Honda Y., Yasuda H., Chiba T., Saya H., Fujii-Kuriyama Y., Nakao M. The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system. J. Biol. Chem. 277:2002;46576-46585
258. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., Roylance R.R., Olpin S., Bevan S., Barker K., Hearle N., Houlston R.S., Kiuru M., Lehtonen R., Karhu A., Vilkki S., Laiho P., Eklund C., Vierimaa O., Aittomaki K., Hietala M., Sistonen P., Paetau A., Salovaara R., Herva R., Launonen V., Aaltonen L.A. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30:2002;406-410
259. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinasetarget of rapamycin-dependent signaling pathway. J. Biol. Chem. 277:2002;27975-27981
260. Trent C., Tsuing N., Horvitz H.R. Egg-laying defective mutants of the nematode Caenorhabditis elegans. Genetics. 104:1983;619-647
261. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., Katschinski D.M., Wenger R.H. The hypoxia-inducible factor-1alpha is a negative factor for tumor therapy. Oncogene. 22:2003;3213-3220
262. Volm M., Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 20:2000;1527-1533
263. Volmat V., Camps M., Arkinstall S., Pouysségur J., Lenormand P. The nucleus, a site for signal termination by sequestration and inactivation of p42p44 MAP kinases. J. Cell Sci. 114:2001;3433-3443
264. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270:1995;1230-1237
265. 2 tension. Proc. Natl. Acad. Sci. USA. 92:1995;5510-5514
266. Warburg O. On the origin of cancer cells. Science. 123:1956;309-314
267. Wax S.D., Rosenfield C.L., Taubman M.B. Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. J. Biol. Chem. 269:1994;13041-13047
268. Welsh S.J., Bellamy W.T., Briehl M.M., Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 62:2002;5089-5095
269. Whitelaw M.L., Gottlicher M., Gustafsson J.A., Poellinger L. Definition of a novel ligand binding domain of a nuclear bHLH receptor: Co-localization of ligand and hsp90 binding activities within the regulable inactivation domain of the dioxin receptor. EMBO J. 12:1993;4169-4179
270. Whitelaw M.L., Gustafsson J.A., Poellinger L. Identification of transactivation and repression functions of the dioxin receptor and its basic helix-loop-helixPAS partner factor Arnt: Inducible versus constitutive modes of regulation. Mol. Cell. Biol. 14:1994;8343-8355
271. Whiteway M., Szostak J.W. The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell. 43:1985;483-492
272. Wiesener M.S., Turley H., Allen W.E., Willam C., Eckardt K.U., Talks K.L., Wood S.M., Gatter K.C., Harris A.L., Pugh C.W., Ratcliffe P.J., Maxwell P.H. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood. 92:1998;2260-2268
273. Wiesener M.S., Munchenhagen P.M., Berger I., Morgan N.V., Roigas J., Schwiertz A., Jurgensen J.S., Gruber G., Maxwell P.H., Loning S.A., Frei U., Maher E.R., Grone H.J., Eckardt K.U. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61:2001;5215-5222
274. Willam C., Masson N., Tian Y.M., Mahmood S.A., Wilson M.I., Bicknell R., Eckardt K.U., Maxwell P.H., Ratcliffe P.J., Pugh C.W. Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc. Natl. Acad. Sci. USA. 99:2002;10423-10428
275. Willis D.M., Loewy A.P., Charlton-Kachigian N., Shao J.S., Ornitz D.M., Towler D.A. Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex. J. Biol. Chem. 277:2002;37280-37291
276. Wilson C.L., Thomsen J., Hoivik D.J., Wormke M.T., Stanker L., Holtzapple C., Safe S.H. Aryl hydrocarbon (Ah) nonresponsiveness in estrogen receptor-negative MDA-MB-231 cells is associated with expression of a variant arnt protein. Arch. Biochem. Biophys. 346:1997;65-73
277. Woods S.L., Whitelaw M.L. Differential activities of murine single minded 1 (SIM1) and SIM2 on a hypoxic response element. Cross-talk between basic helix-loop-helixper-Arnt-Sim homology transcription factors. J. Biol. Chem. 277:2002;10236-10243
278. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., Wilson G.D., Turley H., Talks K.L., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Harris A.L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60:2000;7075-7083
279. Wykoff C.C., Beasley N., Watson P.H., Campo L., Chia S.K., English R., Pastorek J., Sly W.S., Ratcliffe P., Harris A.L. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 158:2001;1011-1019
280. Yao E.F., Denison M.S. DNA sequence determinants for binding of transformed Ah receptor to a dioxin-responsive enhancer. Biochemistry. 31:1992;5060-5067
281. Yasinska I.M., Sumbayev V.V. S-nitrosation of Cys-800 of HIF-1alpha protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett. 549:2003;105-109
282. Yuan Y., Hilliard G., Ferguson T., Millhorn D.E. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem. 278:2003;15911-15916
283. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer. 88:2000;2606-2618
284. Zelzer E., Levy Y., Kahana C., Shilo B.Z., Rubinstein M., Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alphaARNT. EMBO J. 17:1998;5085-5094
285. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835
286. Zhou J., Schmid T., Brune B. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway. Mol. Biol. Cell. 14:2003;2216-2225
287. Zhou J., Schmid T., Frank R., Brune B. PI3KAkt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from p VHL-independent degradation. J. Biol. Chem. 279:2004;13506-13513
288. - tumors. Mol. Cancer Res. 2:2004;89-95
289. Zu X.L., Guppy M. Cancer metabolism: Facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313:2004;459-465
290. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., Stokoe D., Giaccia A.J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:2000;391-396